[1] Yang T, Xu R, You J, et al. Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer. BMC Cancer. 2022 Nov 12;22(1):1168. [2] Tarantino P, Jin Q, Tayob N, et al. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage ...
locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182.
4.Schettini F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021. 5.Matutino A, et al. Current Oncology. Hormone receptor-positive, HER2-negative meta...
2011年1月至2018年12月期间,日本东京癌研有明医院(Cancer Institute Hospital of JFCR)连续800例不可手术、晚期或复发的G/GEJ 腺癌患者接受了氟嘧啶和铂类联合治疗作为一线治疗。25例患者在新辅助或辅助化疗后6个月内出现早期复发,7例患有其他晚期癌症,18例最初在其他医院接受全身化疗,12例未检测HER2状态。此外,...
[18]Trastuzumab deruxtecan(T-DXd;DS-8201)in patients with HER2-low,advanced gastric or gastroesophageal junction(GEJ)adenocarcinoma:Results of the exploratory cohorts in the phase II,multicenter,open-label DESTINY-Gastric01 study.2020 ESMO Mini Oral 1422. ...
In multivariate Cox regression analysis, HER2-null status was associated with worse survival (hazard ratio 3.01; 95% confidence interval 1.18–7.65; and P =0.02).This study highlights the prognostic importance of low HER2 expression in gastric cancer, similar to that observed in HER2 -low-...
Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial [J]. J Clin Oncol, 2023, 41(4):816-825. DOI:...
12. Bhavsar D, Kazlauskas L, Michelini F, Griffin M, Wilson M, Cecchi F, et al. Abstract 3999: Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumors. Cancer Research 2023; 83(7_Supplement):3999-3999. ...
49.Modi S,Jacot W,Iwata H,et al.Trastuzumab deruxtecan(T-DXd)versus treatment of physician’s choice(TPC)in patients(pts)with HER2-low unresectable and/or metastatic breast cancer(mBC):UpDate:survival results of the randomized,phase 3 DESTINY-Breast04 study.2023 ESMO 376O. ...
基于DESTINY-Breast04试验的结果，德曲妥珠单抗(5.4mg/kg) 在40多个国家被批准用于治疗不可切除或转移性 HER2-low（IHC 1+ 或 IHC 2+/ISH 阴性）乳腺癌的成人患者，这些患者在转移阶段中接受过一次全身治疗或在完成辅助化疗期间或六个月内疾病复发。德曲妥珠单抗 (5.4mg/kg)已在以色列、日本获批，并在美国...